TY - JOUR
T1 - VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma
T2 - A Wisconsin Oncology Network study
AU - Chang, Julie E.
AU - Peterson, Christopher
AU - Choi, Sangbum
AU - Eickhoff, Jens C.
AU - Kim, Kyungmann
AU - Yang, David T.
AU - Gilbert, Leslie A.
AU - Rogers, Eric S.
AU - Werndli, Jae E.
AU - Huie, Michael S.
AU - Mcfarland, Thomas A.
AU - Volk, Michael
AU - Blank, Jules
AU - Callander, Natalie S.
AU - Longo, Walter L.
AU - Kahl, Brad S.
PY - 2011/10
Y1 - 2011/10
N2 - Intensive chemotherapy regimens are not feasible in many adults with mantle cell lymphoma (MCL). We sought to build upon our previous experience with a non-intensive regimen, modified R-hyperCVAD chemotherapy (rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone) with maintenance rituximab (MR), by the incorporation of bortezomib (VcR-CVAD) and the extension of MR beyond 2years. Patients with previously untreated MCL received VcR-CVAD chemotherapy every 21d for six cycles. Patients achieving at least a partial response to induction chemotherapy received rituximab consolidation (375mg/m 2×4weekly doses) and MR (375mg/m 2 every 12weeks×20 doses). The primary end points were overall and complete response (CR), and secondary endpoints were progression-free (PFS) and overall survival (OS). Thirty patients were enrolled, with a median age of 61years. All patients had advanced stage disease, and 60% had medium/high MCL International Prognostic Index risk factors. A CR or unconfirmed CR was achieved in 77% of patients. After a median follow-up of 42months, the 3-year PFS and OS were 63% and 86%, respectively. The observed 3-year PFS and OS with VcR-CVAD in MCL were comparable to reported outcomes with more intensive regimens. A cooperative group trial (E1405) is attempting to replicate these promising results.
AB - Intensive chemotherapy regimens are not feasible in many adults with mantle cell lymphoma (MCL). We sought to build upon our previous experience with a non-intensive regimen, modified R-hyperCVAD chemotherapy (rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone) with maintenance rituximab (MR), by the incorporation of bortezomib (VcR-CVAD) and the extension of MR beyond 2years. Patients with previously untreated MCL received VcR-CVAD chemotherapy every 21d for six cycles. Patients achieving at least a partial response to induction chemotherapy received rituximab consolidation (375mg/m 2×4weekly doses) and MR (375mg/m 2 every 12weeks×20 doses). The primary end points were overall and complete response (CR), and secondary endpoints were progression-free (PFS) and overall survival (OS). Thirty patients were enrolled, with a median age of 61years. All patients had advanced stage disease, and 60% had medium/high MCL International Prognostic Index risk factors. A CR or unconfirmed CR was achieved in 77% of patients. After a median follow-up of 42months, the 3-year PFS and OS were 63% and 86%, respectively. The observed 3-year PFS and OS with VcR-CVAD in MCL were comparable to reported outcomes with more intensive regimens. A cooperative group trial (E1405) is attempting to replicate these promising results.
KW - Bortezomib
KW - Chemotherapy
KW - Mantle cell lymphoma
KW - Non-Hodgkin lymphoma
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=80053567237&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2011.08820.x
DO - 10.1111/j.1365-2141.2011.08820.x
M3 - Article
C2 - 21848883
AN - SCOPUS:80053567237
SN - 0007-1048
VL - 155
SP - 190
EP - 197
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 2
ER -